In a nutshell This study is evaluating the safety and effectiveness of a new drug called lisocabtagene maraleucel compared to standard chemotherapy for relapsed (recurrent) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be time to any disease-related complication. The...
Read MorePerformance status -1 – Slightly symptomatic Posts on Medivizor
Searching for patients with relapsed or refractory Hodgkin’s lymphoma to try pembrolizumab plus GVD
In a nutshell This trial is evaluating the effects of second-line pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, doxorubicin) for relapsed (recurrent cancer) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). The main outcome to be measured is the number of patients who achieve a complete response...
Read MoreSearching for patients with relapsed/refractory Hodgkin lymphoma to test BV-ICE treatment
In a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...
Read MoreIbrutinib in combination with bendamustine and rituximab improves quality of life factors in patients with severe impairment
In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...
Read MoreSearching for patients with relapsed or refractory follicular lymphoma to test the effectiveness of TGR-1202
In a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read MoreSearching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial
In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...
Read MoreSearching for patients to test the effectiveness of venetoclax with ibrutinib in treating chronic lymphocytic leukemis
In a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...
Read MoreLooking for patients with untreated mantle cell lymphoma to test the effectiveness of a combination therapy including acalabrutinib
In a nutshell This phase 3 clinical trial will test the effectiveness of acalabrutinib (ACP-196) with rituximab (Rituxan) and bendamustine (Treanda) in treating patients with previously untreated mantle cell lymphoma. The primary outcome will be measured by the time until the disease progresses. The details Acalabrutinib is an investigational...
Read MoreThe effects of brentuximab vedotin on quality of life
In a nutshell This trial examined the quality-of-life (QOL) impact of an antibody therapy among patients who had already undergone standard treatment for relapsed- or refractory disease. The authors concluded that the treatment modestly decreased QOL during certain time periods only. Some background Hodgkin Lymphoma is generally highly...
Read More
